in an attempt to maximize the therapeutic index and to overcome the large variations in 1-beta-d-arabinofuranosylcytosine ( ara-c ) plasma levels and host toxicities that have been documented with standard hdara-c regimens ( 3 g/m2 over 3 h every 12 h x 8 or x12 doses ) , pediatric patients with acute lymphocytic leukemia or lymphoma in relapse were treated with a regimen of loading bolus followed immediately by continuous infusion of ara-c .
C0010711
arabinofuranosylcytosine
C0024299
lymphoma